June verdict expected for BMS' Opdivo in lung cancer
This article was originally published in Scrip
Executive Summary
The FDA has granted a priority review to Bristol-Myers Squibb's application for Opdivo (nivolumab) as a treatment for patients with advanced squamous non-small cell lung cancer (NSCLC) after prior therapy.